Form 4: Abbott Laboratories Director John G. Stratton Reports Acquisition of Stock Equivalent Units

Director John G. Stratton reports acquiring 353 stock equivalent units of Abbott Laboratories on June 30, 2024, at a price of $103.91 per unit.

Summary

• On June 30, 2024, John G. Stratton, a director of Abbott Laboratories, acquired 353 stock equivalent units.
• These units were credited to a stock equivalent unit account under a grantor trust.
• The price per unit was $103.91.
• These units earn the same return as if the fees were invested in Abbott shares and are generally paid in cash at age 65 or upon retirement from the board.
• Following the transaction, Stratton's balance of stock equivalent units is 10,895, which includes units acquired through dividend reinvestment.
• The report was filed on July 2, 2024.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a routine transaction indicating alignment of director interests with the company's performance. There are no negative implications.

Positives

• The acquisition of stock equivalent units reflects continued alignment of the director's interests with the company's performance.

Future Outlook

The stock equivalent units will continue to accrue value based on Abbott's share performance and will be paid out in cash upon retirement or at age 65.

Industry Context

This filing is a routine disclosure related to director compensation and holdings, common among publicly traded companies. It provides transparency regarding the alignment of director interests with shareholder value.

Comparison to Industry Standards

• Director compensation packages often include stock or stock-equivalent units to align director interests with shareholder value, similar to practices at companies like Johnson & Johnson (JNJ) and Medtronic (MDT).
• The use of grantor trusts for holding these units is a common method for deferring compensation and managing tax implications, comparable to arrangements seen at Pfizer (PFE) and Merck (MRK).

Stakeholder Impact

• The transaction has a minor positive impact on shareholders by demonstrating that the director's interests are aligned with the company's long-term success.

Key Dates